board of directors

Jay Venkatesan, MD, MBA

President, Chief Executive Officer, and Chairman

Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

Itzhak Goldberg, MD, FACR

Director & Chairman Emeritus

Dr Goldberg founded Angion in 1998. Prior to Angion, Dr. Goldberg was a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. Dr. Goldberg has made seminal contributions in the field of tyrosine kinase receptors and hepatocyte growth factor research and has been the driving force within Angion since he started the company. Under Dr. Goldberg’s leadership, Angion received continuous non-dilutive NIH, DOD, and NSF grants and successfully raised Series A/B funding.

Victor F. Ganzi, JD

Lead Independent Director

Mr. Ganzi has been a member of our board of directors since April 2018. He has served as Non-Executive Chairman of the board of directors of Willis Towers Watson (Nasdaq: WLTW), a global advisory, broking and solutions company, since January 2019 and as a director since January 2016. Previously, he served as a director of Towers Watson beginning on January 1, 2010, as Chairman of Towers Watson’s Audit Committee, and a member of its Nominating and Governance Committee. Mr. Ganzi is presently a consultant and corporate director, serving on the boards of numerous private and not-for-profit organizations, including PGA Tour, Inc., the National Center on Addiction and Substance Abuse, the Whitney Museum of American Art and the Madison Square Boys and Girls Club. Mr. Ganzi was the President and Chief Executive Officer of The Hearst Corporation, a private diversified communications company, from 2002 to 2008. He served as Hearst’s Executive Vice President from 1997 to 2002 and as its Chief Operating Officer from 1998 to 2002. Prior to joining Hearst in 1990, Mr. Ganzi was the managing partner at the international law firm of Rogers & Wells (now part of Clifford Chance). Mr. Ganzi previously served as a director of Gentiva Health Services, Inc., Wyeth and Hearst-Argyle Television, Inc. Mr. Ganzi has a B.S. in Accounting summa cum laude, from Fordham University, a J.D. from Harvard Law School and an L.L.M. in Taxation from New York University.

Allen R. Nissenson, MD

Director

Dr. Nissenson has been a member of our board of directors since January 2020. From March 2014 to December 2019, he served as the Chief Medical Officer of DaVita Kidney Care, a provider of kidney care services. He is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA, where he has served since August 2008 and where he previously served as Director of the Dialysis Program and Associate Dean from July 2005 to August 2008. Dr. Nissenson is the chair of Kidney Care Partners and co-chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association (RPA) and current member of the Government Affairs Committee. Dr. Nissenson also previously served as president of the Southern California End-Stage Renal Disease Network, as well as chair of the Medical Review Board. He served as a Robert Wood Johnson Health Policy Fellow of the Institute of Medicine from 1994 to 1995 and worked in the office of the late Senator Paul Wellstone.

Dr. Nissenson has an M.D. from Northwestern University Medical School and is the recipient of various awards, including the President’s Award of the National Kidney Foundation, the Lifetime Achievement Award in Hemodialysis, the American Association of Kidney Patients’ (AAKP) Medal of Excellence Award and, in 2017, the RPA Distinguished Nephrology Service Award.

Gilbert S. Omenn, MD, PhD

Director

Dr. Omenn has been a member of our board of directors since January 2020. Since 1997, Dr. Omenn has been a faculty member at the University of Michigan, where he is currently the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. Earlier, he was the dean of the School of Public Health and Community Medicine and professor of medicine at the University of Washington. Dr. Omenn served as Executive Vice President for Medical Affairs of the University of Michigan and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. Dr. Omenn is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. He chaired the Presidential/ Congressional Commission on Risk Assessment and Risk Management, the NAS/NAE/IOM Committee on Science, Engineering, and Public Policy, and the Advisory Committee for the Agency for Toxic Substances and Disease Registry. He served on the National Commission on the Environment, the NIH Scientific Management Review Board, and the CDC Director’s Advisory Committee. He is a past president of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Since 2014, Dr. Omenn has served as a director of Galectin Therapeutics Inc., a biotechnology company (Nasdaq: GALT). Dr. Omenn previously served as a director of Amgen, Inc. for 27 years and Rohm & Haas Corporation for 22 years. Dr. Omenn was a director of Esperion Therapeutics (Nasdaq: ESPR) from August 2014 to May 2018. Dr. Omenn has a B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School and Ph.D. in genetics from the University of Washington.

Karen Wilson

Director

Karen J. Wilson has served as a member of our board of directors since April 2020. Ms. Wilson has more than 30 years of industry and leadership experience in life sciences companies across finance, strategy, and risk management. She currently serves as independent director and audit committee chair for Connect Biopharma, LAVA Therapeutics, and Vaxart, Inc.  Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a pharmaceutical company, until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz in 2011, she served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. She previously served as a principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte & Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant in the State of California and received a B.S. in Business from the University of California, Berkeley.